Prognostic relevance of the Ki-67 proliferation index in patients with mantle cell lymphoma.
- Author:
Tae Dong JEONG
1
;
Hyun Sook CHI
;
Min Sun KIM
;
Seongsoo JANG
;
Chan Jeoung PARK
;
Joo Ryung HUH
Author Information
- Publication Type:Original Article
- Keywords: Bone marrow; Ki-67 proliferation index; Mantle cell lymphoma; Prognosis
- MeSH: Biopsy; Bone Marrow; Diagnosis; Humans; Lymphoma, Mantle-Cell*; Prognosis; Survival Rate
- From:Blood Research 2016;51(2):127-132
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: A high Ki-67 proliferation index (PI) in neoplastic cells is associated with poor survival in mantle cell lymphoma (MCL). We aimed to determine the cut-off values for the Ki-67 PI as a prognostic factor in MCL according to bone marrow findings. METHODS: Immunohistochemical (IHC) staining for Ki-67 was performed on formalin-fixed paraffin-embedded biopsy tissues from 56 patients with MCL. Patients were grouped based on their Ki-67 PI values. Survival analyses were carried out and the cut-off value for the Ki-67 PI was determined. RESULTS: Of the 56 patients, 39 (69.6%) showed bone marrow involvement of MCL; 21 of these patients had leukemic manifestations at the time of diagnosis. The results of the Ki-67 IHC staining were as follows: ≤10% in 22 patients, 11-20% in 14 patients, 21-30% in 3 patients, 31-40% in 4 patients, 41-50% in 4 patients, and >50% in 9 patients. A cut-off value of 20% revealed significantly different survival rates with mean survival times of 69.8 months (Ki-67 PI≤20%) and 47.9 months (Ki-67 PI>20%), irrespective of bone marrow findings (P=0.034). Clinical outcomes did not differ, regardless of bone marrow findings. However, in cases with bone marrow involvement, the Ki-67 cut-off value of 30% for overall survival was required to yield statistical significance (P=0.033). CONCLUSION: The 20% cut-off value for the Ki-67 PI was clinically meaningful, regardless of bone marrow involvement of MCL. For patients with bone marrow involvement, the statistically significant cut-off value increased to 30%.
